EXCLUSIVE: FibroBiologics Announces First Patients Dosed In Phase 1/2 Clinical Trial for Diabetic Foot Ulcers; CYWC628 Is Multicenter Phase 1/2 Clinical Study of Fibroblast Cell Therapy In Australia

Loading news article.

EXCLUSIVE: FibroBiologics Announces First Patients Dosed In Phase 1/2 Clinical Trial for Diabetic Foot Ulcers; CYWC628 Is Multicenter Phase 1/2 Clinical Study of Fibroblast Cell Therapy In Australia | WAPE

EXCLUSIVE: FibroBiologics Announces First Patients Dosed In Phase 1/2 Clinical Trial for Diabetic Foot Ulcers; CYWC628 Is Multicenter Phase 1/2 Clinical Study of Fibroblast Cell Therapy In Australia

Article summary

Related companies

Comments —